Journal of Alzheimer's Disease xx (20xx) Background: Preclinical Alzheimer's disease (AD) is defined by cerebral amyloid-␤ positivity (A␤+) in cognitively normal (CN) older adults. Objective: To estimate the risk of progression to the symptomatic stages of AD due to PET A␤+ and the extent that progression was influenced by other demographic, genetic, and clinical characteristics in a large prospective study. Methods: Fine-Gray subdistribution modeling was used to examine the risk of progression from CN to MCI/dementia due to A␤+, APOE 4 carriage, and their interaction in the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging CN cohort (n = 599) over 8 years.
INTRODUCTION
Clinical-pathological models propose that Alzheimer's disease (AD) begins with accumulation of amyloid-␤ (A␤) followed by aggregation of tau, which result in cortical atrophy, cognitive decline and, ultimately, dementia [1, 2] . Biomarker studies using positron emission tomography (PET) neuroimaging or cerebrospinal fluid (CSF) sampling show that A␤ accumulation begins up to 20 years prior to the onset of dementia [3] . According to these models, cognitively normal (CN) older adults with elevated levels of A␤ (A␤+) are in the preclinical stages of AD [2, 4] . Even though CN A␤+ individuals are clinically asymptomatic, preclinical AD is characterized by subtle progressive cognitive decline, primarily in episodic memory [5] , which may reflect insidious loss of cortical brain volume due to A␤+ [6] [7] [8] . Prospective studies in both experimental and epidemiological cohorts have indicated that CN A␤+ adults have higher risk of progression to clinical classification of mild cognitive impairment (MCI) or dementia compared to those without elevated A␤ (i.e., A␤-) [9, 10] . Clinical trials of A␤-lowering drugs have endeavored to recruit CN A␤+ older adults based on their increased risk for incident MCI/dementia in an attempt to slow cognitive decline and prevent onset of symptomatic AD (e.g. Clinical Trials NCT02569398 and NCT02008357) [11] . Furthermore, recently proposed guidance from the US Food and Drug Administration (FDA) acknowledges the centrality of biomarkers such as A␤+ for recruitment of participants for early AD clinical trials, where Stage 0 includes individuals who are asymptomatic but have evidence of AD pathophysiologic changes [12] . Understanding the risk of progression to MCI/dementia associated with A␤+ over the long time periods characteristic of preclinical AD is therefore necessary to inform models of disease etiology and guide recruitment and outcome expectations in clinical trials or clinical studies of preclinical AD and AD.
Incidence of progression to MCI/dementia in large samples of A␤+ CN adults ranges from 17.7% over an average of 3.7 years in the Mayo Clinic Study of Aging (MCSA, mean age 76) [10] , 26 .4% over 5 years in the Knight Alzheimer's Disease Research Center study (Knight ADRC, mean age 72) [13] , 19% over 6 years in the Australian Imaging, Biomarkers and Lifestyle study (AIBL, mean age 73) [14] , to 32.2% over an average of 4 years in the Alzheimer's Disease Neuroimaging Initiative (ADNI, mean age 74) [15] . In all studies, the incidence of progression was at least two times greater in A␤+ compared to A␤-. Together, these studies show that A␤+ increases risk for clinical disease progression in CN adults, although the error associated with some risk estimates is increased by the small sample sizes at the longer follow-up intervals [16] . For example, in ADNI, data beyond 4 years were available for 16% of the initial A␤+ sample [15] . Similarly, estimates of progression at 5 years were based on 25% of the baseline MCSA sample [10] , and 35% of the Knight ADRC data were available beyond 5 years [17] . These small samples limit the use of complex analyses to examine the influence of other characteristics proposed to hasten progression to symptomatic disease (e.g., age, interactions between apolipoprotein E (APOE) 4 carriage and A␤ status) [18] . APOE 4 carriage is associated with increased risk of both A␤+ and dementia in CN older adults [19, 20] , and neuropsychological studies show that A␤+ APOE 4 carriers experience greater cognitive decline than A␤+ APOE 4 non-carriers [18, 21, 22] ; therefore, the prognostic value of A␤ and APOE 4 may be increased by examining their effects combined. Finally, although there is evidence that vascular and metabolic conditions increase risk of cognitive impairment and dementia in CN adults [23, 24] , few studies have sought to account for their influence on estimates of A␤-associated clinical progression. Although the prevalence of vascular disease in the population-based MCSA is higher than that found in controlled experimental samples [25] , it was reported that adjustment for vascular diseases did not change their progression risk estimates [10] . Whether this remains the case in a large experimental cohort is yet to be seen.
The first aim of this study was to examine the incidence of A␤-associated progression to MCI/dementia among CN older adults. The second aim was to identify demographic and clinical characteristics that moderate the relationship between A␤ status and progression. The first hypothesis was that A␤+ would be associated with greater risk of clinical disease progression over 8 years. The second hypothesis was that A␤-associated progression to MCI/dementia would be increased further by APOE 4 carriage. Post-hoc analyses explored how demographic and clinical risk factors influenced clinical disease progression in A␤+ and A␤-CN adults.
METHODS

Participants
Participants were enrolled in the AIBL flagship study of aging, details of which have been described elsewhere [26] . Briefly, volunteers were excluded from entry if they had any of the following: non-AD dementia, history of schizophrenia or bipolar disorder, current depression (Geriatric Depression Scale score >5), Parkinson's disease, cancer (other than basal cell skin carcinoma) within the last 2 years, symptomatic stroke, uncontrolled diabetes, obstructive sleep apnea, past head injury with >1 hour of post-traumatic amnesia, or current regular alcohol intake above recommended limits [27] . Health status at each study visit was determined from clinical assessment comprising measurement of vital signs (height, weight, waist circumference, and blood pressure using an electric sphygmomanometer) and self-reported medical history. Blood pathology for all participants was assessed at baseline. All included participants were identified to have no, or medically well-controlled systemic illnesses at baseline. Ethics approval for the AIBL study was granted by St Vincent's Health, Austin Health, and Edith Cowan University, and written informed consent was collected from all participants prior to clinical and neuropsychological assessment at every 18-month interval.
Currently, the AIBL study includes 787 CN adults aged above 60 years who have undergone A␤ PET neuroimaging. Participants were recruited in two waves: an inception cohort (n = 444) followed for up to 8 years, and an enrichment cohort (n = 343) followed for up to 4.5 years. Of the initial cohort, 70.5% have remained active in the study for all visits up to 8 years. This study sample was restricted to those who attended at least two visits over the 8-year period (n = 621). Data for 19 participants with inconsistent clinical classification (n = 16) or A␤ status (n = 3) during the study period were excluded from all analyses. Twenty participants had incomplete covariate data, which were imputed based on information contained in their clinical visit notes where possible. One participant who met exclusion criteria but was inadvertently included in the AIBL study was also excluded. Thus, the total sample for this study consisted of 599 older adults (Fig. 1) . 
Clinical classification of cognitive status
An expert clinical panel reviewed all available neuropsychological and psychiatric information for participants at each visit based on neuropsychologist referral. They were blinded to information about A␤ and APOE 4 status, and consensus classifications were made using standard clinical criteria for MCI [28] and AD [29] . Participants classified with MCI/dementia during the follow-up period were coded as "progressors"; participants who did not meet those criteria were classified CN.
Measures
Self-reported history of stroke/TIA at any time before or during the study period and current hypertension or diabetes was recorded. APOE 4 carriage was determined from whole blood extracted DNA [30] , and fasting glucose and lipid concentrations were measured. Body mass index (BMI) was calculated using height and weight (kg/m 2 ). Education was coded as ≤12 years or >12 years. Baseline mood was assessed using the Hospital Anxiety and Depression Scale (HADS) [31] , and the Memory Complaint Questionnaire (MAC-Q) [32] was used to assess subjective memory complaint.
Amyloid PET neuroimaging
PET neuroimaging was conducted using one of the following A␤ radiotracers: 11 C-Pittsburgh compound-B (PiB, n = 216), 18 F-NAV4694 (NAV, n = 56), 18 F-Florbetapir (FBP, n = 158), or 18 FFlutemetamol (FLUTE, n = 169). PET methods and procedures have been reported previously [33, 34] . Briefly, PET acquisitions were performed up to 90 min following tracer injection. Standardized uptake value (SUV) data were summed and normalized to a reference region (the cerebellar cortex for PiB and NAV, the whole cerebellum for FBP, and the pons for FLUTE) to generate a SUV ratio (SUVR). Threshold values for elevated A␤ deposition vary by radiotracer, so a linear regression transformation was applied to the FBP and FLUTE SUVR to create a "PiB-like" SUVR unit called Before the Centiloid Kernel Transformation (BeCKeT) [34] . All participants with SUVR/BeCKeT≥1.40 at their most recent PET scan were classified A␤+ and those below the threshold were classified A␤-; however, participants whose SUVR/BeCKeT fluctuated around the threshold on multiple PET scans could not be accurately classified and were therefore excluded from all analyses.
Statistical analyses Baseline group differences
All continuous variables were assessed for normality by visual inspection of Q-Q plots. Between-group comparisons for A␤ status were conducted using a one-way analysis of variance (ANOVA) for normally distributed variables. Kruskal-Wallis one-way ANOVAs were used for non-normally distributed variables. Fisher's exact tests were used for dichotomous variables. Effect sizes (Cohen's d) were calculated for all comparisons reaching statistical significance.
Survival analysis
Fine-Gray subdistribution hazards models were fit to examine risk of clinical disease progression in the presence of competing risks. Progression to MCI/dementia were coded as events, and time to event or censoring was entered in months from the baseline visit. Death or withdrawal from the study due to illness were coded as competing risks because the deceased have no risk of clinical progression and those who withdraw due to illness may have higher risk [35] . Schoenfeld residuals tests indicated that the proportional hazards assumption was met. No outliers were detected.
Survival models evaluated the main hypotheses in 5 stages. Model 1 included characteristics that differed between A␤ groups at baseline (age, hypertension, and BMI). Model 2 added A␤ status, and Model 3 added APOE 4 status. To examine the effects of health factors proposed to influence disease progression, diabetes and stroke/TIA were added in Model 4. Finally, Model 5 included an A␤ status by APOE 4 interaction to compare the hazard of progression between participants who had both A␤+ and APOE 4 against all other participants. Sex and education were not included in these models because no baseline differences were observed between A␤ groups on these factors. Hazard ratios with 95% confidence intervals were calculated, and the cumulative hazard functions were plotted. All statistical analyses were performed using R version 3.4.3 and SPSS 23, with statistical significance at p < 0.05. Results were interpreted on the basis of the hazard ratios and confidence intervals; therefore, no adjustments were made for multiple comparisons.
Post-hoc analyses
Model 4 was repeated within the A␤+ and A␤-groups separately to examine differences in risk of clinical disease progression associated with A␤ status. These analyses used continuous PET SUVR/BeCKeT to assess the relative effect of A␤ deposition on progression within the pre-defined ranges for the A␤-and A␤+ groups.
RESULTS
Sample characteristics and attrition
Details of the study sample are shown in Fig. 1 . Of the 599 included participants, 74 progressed to MCI or dementia over the 8-year period (CN->MCI->dementia = 7, CN->MCI = 58, CN->dementia = 9; median time to progression: 36.5 months, ranging from 16-94 months). During the study period, 15 participants died, 20 withdrew due to ill health (3 of whom did so after progressing), 50 withdrew formally from the study and 4 were not contactable for follow-up. The median follow-up time was 88 months (interquartile range 54).
Average age of participants was 70 (range 60-90), and 55.8% had >12 years of education. Demographic and clinical characteristics, and prevalence of vascular and metabolic risk factors are shown in Table 1 . Table 1 summarizes the differences between A␤ groups at baseline. A␤+ participants were 3 years older on average and more likely to be APOE 4 carriers (odds ratio (OR): 3.45, 95% confidence 
Baseline group differences
Risk of progression to MCI or dementia
A␤+ participants were significantly more likely to progress to MCI/dementia than A␤-(17.7% vs 8.1%, OR: 2.43, 95% CI: 1.47-4.03). In all 5 survival models, every additional year of age at baseline conferred greater risk (7%) of progressing over the 8-year period for all participants (Table 2) . In Model 2, A␤+ status increased the risk of progression by 104% (Fig. 2a) . In Model 3, APOE 4 carriers had 114% greater risk than non-carriers (Fig. 2b) . The risk conferred by A␤+ was mediated by the addition of APOE 4 into the model. Model 4 showed that the health factors had no influence on risk of progression, nor did they mediate risk due to A␤+; no interactions were observed in post-hoc analyses. In Model 5, the A␤ and APOE 4 interaction was significant: A␤+ APOE 4 carriers had 348% greater risk of progressing to MCI/dementia compared to all other participants. Further analysis showed that progression risk in A␤+ APOE 4 non-carriers (hazard ratio (HR): 1.08, 95% CI: 0.56-2.07) and A␤-APOE 4 carriers (HR: 0.72, 95% CI: 0.21-2.45) was not significantly greater than in A␤-APOE 4 non-carriers (Fig. 2c) ; therefore, it was appropriate to combine these three groups in the interaction analysis.
Clinical disease progression within Aβ+ and Aβ-groups
Examination of risk factors within the A␤+ group showed that higher age, higher PET SUVR/BeCKeT, and APOE 4 carriage increased risk of progression (Table 3) . Risk increased by 5% for each additional year of age at baseline, and by 149% for every whole PET SUVR/BeCKeT unit increase. Lastly, risk of progression was 163% greater with APOE 4 carriage. Within the A␤-group, the only risk factor for progression to MCI/dementia was higher age (9%). Overlap in 95% confidence intervals were observed for all predictor variables between A␤+ and A␤-groups, although these overlaps were smallest for APOE 4 carriage and PET SUVR/BeCKeT. The degree of overlap suggests that APOE 4 carriage and greater A␤ deposition increased risk of progression for the A␤+ group but not for the A␤-group, and that this difference was significant [36] .
DISCUSSION
Rates of A␤+ progression from CN to MCI/dementia in the AIBL sample and the associated risk factors for both A␤-and A␤+ progression over 8 years are reported for the first time. The results supported the first hypothesis that A␤+ would be associated with greater risk of progression to MCI/dementia. Eight-year risk of progression to MCI/dementia in CN A␤+ adults from the AIBL study was increased by 65-104% compared to A␤- (Table 2 ). This indicates that A␤+ is an important prognostic marker for progression to MCI/dementia in CN older adults. The second hypothesis, that A␤-associated risk for progression to MCI/dementia would be increased further by APOE 4 carriage, was also supported. The large sample studied here allowed the risk of progression conferred by concurrent A␤+ and APOE 4 carriage to be estimated, taking into account health factors posited to influence progression to MCI/dementia as well as competing risks such as death or withdrawal due to illness. Risk of progression to MCI/dementia was 348% greater in A␤+ APOE 4 carriers compared to all other participants ( Table 2) . Similar findings were observed in the MCSA, although their risk estimate was reported relative to A␤-APOE 4 non-carriers (190%) [37] . In this study, no difference in risk was observed between A␤-APOE 4 non-carriers, A␤-APOE 4 carriers and A␤+ APOE 4 non-carriers, suggesting an additive effect between A␤+ and APOE 4 carriage that is greater than the sum of their individual contributions. This is consistent with results of neuropsychological studies showing that CN A␤+ APOE 4 carriers experience greater cognitive decline over time with earlier onset [18, 21, 22, 38] . In agreement with a recent report that episodic memory performance remains stable in A␤-regardless of APOE 4 status, APOE 4 carriage did not increase the risk of clinical disease progression in A␤- (Fig. 2c) [38] . Previous research shows that APOE 4 reduces clearance of cerebral A␤ but does not affect rates of A␤ production [39] ; therefore, the findings of this study indicate that the impaired clearance of A␤ due to APOE 4 is most clinically significant in individuals who have high levels of A␤.
As progression to MCI/dementia was observed in a small number of individuals with normal A␤ levels (8.1%), risk factors within the A␤+ and A␤-groups were investigated. Previous studies indicate that health conditions such as hypertension, diabetes, or stroke/TIA can contribute to cognitive decline and clinical disease progression in older adults [23, 24, 40] . Although higher prevalence of hypertension and lower BMI was observed in the A␤+ group, these differences were very small. Thus, both groups had similar cardiovascular risk profiles and these factors did not influence risk of progression within either A␤ group. For both A␤ groups, higher age at baseline was associated with increased risk of progression to MCI/dementia (Table 3) . Although A␤ deposition, and therefore risk of disease progression, is known to increase with age [41] , other neuropathological processes such as brain atrophy are also associated with age [42] . Higher relative A␤ deposition increased progression risk in the A␤+ group by 150%; however, PET SUVR/BeCKeT for A␤-progressors was not near the threshold for A␤+ (median 1.16, range 1.02-1.39) making it unlikely that progression in the A␤-group was due to any unrecognized increase in A␤. While it remains unknown whether abnormal levels of A␤ deposition play a causative role in the development of dementia due to AD, the recent NIA-AA Research Framework proposed that AD be defined by the presence of cortical A␤ and tau aggregates and neurodegeneration rather than by clinical symptoms due to the poor specificity of cognitive symptoms to detect AD neuropathological processes [4] . Taken together, these data suggest that A␤-associated clinical progression is consistent with AD neuropathological changes, whereas progression in the absence of elevated A␤ deposition is the result of disease processes other than AD that accumulate with age [43] . This indicates that the prognostic value of A␤+ is specific to dementia due to AD. Despite the longer time interval and greater statistical control over demographic, health and clinical characteristics, the 17.7% incidence of progression due to A␤+ was consistent with that observed previously over 6 years (19%) in the AIBL sample [14] . However, the current 8-year estimate of A␤-associated progression remained lower than those reported in the ADNI (32.2%) and Knight ADRC (26.4%) cohorts over similar time periods [15, 44] , and was equal to that reported by the MCSA (17.7%) over an average of 3.7 years [10] . The relatively lower incidence of progression in AIBL may reflect differences in the samples studied and the respective inclusion/exclusion criteria. For example, the ADNI and Knight ADRC cohorts were, on average, 2-4 years older than AIBL and the MSCA cohort was 6 years older than the AIBL cohort. The populationbased MCSA cohort reports higher prevalence of risk factors other than A␤+ for MCI/dementia: at baseline, 79.4% of the MCSA participants had hypertension, 18.7% had diabetes, and 14.3% had history of stroke [25] , compared to 38.8%, 7.3% and 1.8%, respectively, in the AIBL CN cohort. Despite the increased presence of these factors and older age in the MCSA, the estimates of A␤-associated progression were similar and may also reflect comparable methods for measuring A␤ deposition and defining A␤+ using PET; however, the follow-up time for the MCSA was shorter than that for AIBL and may be expected to increase with similar follow-up. It is also possible that the higher incidence of disease progression in the other samples reflects some unreliability in their estimates due to small sample size or differences in method of A␤+ classification. Both ADNI and Knight ADRC used different cut-off values and either PET neuroimaging or CSF amyloid sampling to classify A␤ status across participants, while both AIBL and the MCSA used only PET to measure A␤ levels in all participants; therefore, differences between the A␤+ samples identified in these studies may also reflect different prospective estimates of incident MCI/dementia. Measuring A␤ levels with a common method for all participants rather than using different biomarkers to do so will increase the reliability of classification. Finally, the methods utilized to define clinical status vary across the different studies. The Knight ADRC relies on CDR score to classify participants and, while AIBL and the MCSA both use a consensus panel to determine clinical status, these panels define cognitive impairment differently (≤-1.5 SD on two tests versus ≤-1 SD on one domain score). ADNI also utilizes clinical consensus classifications; however, the public availability of this data has meant different researchers have also utilized CDR ratings and actuarial neuropsychological approaches to define clinical status, which itself has resulted in different estimates of A␤-associated progression [15, 46, 47] . These varying approaches to clinical classification and sample selection may explain the differences in estimates of A␤+ progression between studies. Findings of consistency or inconsistency in outcomes between different samples is crucial because this provides information about the effects of potential sampling bias associated with the different studies on models of disease progression and the disease processes reported from these individual cohorts. Lower incidence of progression in the current study may reflect the larger sample sizes at longer follow-up times, the more stringent criteria for cognitive impairment, the use of consensus classification, and the more exclusive sample when compared to the other large studies of preclinical AD. Nonetheless, these data indicate that A␤+ is an important factor for clinical disease progression in AD.
A recent consensus group reported the importance of established and putative risk factors for dementia among older adults, and stated that the predictive value of A␤+ for progression to MCI/dementia was equivocal over 3 years [48] . While they agreed that age and APOE 4 carriage were important risk factors of clinical progression to symptomatic disease, these factors are non-modifiable. The group, therefore, considered other potentially modifiable risk factors and concluded that hearing loss, hypertension and obesity in midlife, and smoking, depression, physical inactivity, social isolation, and diabetes in late-life held greater prognostic utility than did A␤ [48] . The present study examined risk factors for progression accounting for age and APOE 4 carriage and showed that A␤+ was a strong predictor of clinical disease progression in CN adults over 8 years, while health factors such as hypertension, diabetes and obesity were not. The current findings converge with that from other prospective studies of A␤+ risk for MCI/dementia, suggesting that the consensus position be reconsidered with data from longer prospective studies, given that the preclinical stages of AD can extend for up to 20 years [3] . Some aspects of this study limit the generalizability of its findings to a wider population. First, the AIBL study utilized a convenience sample and recruited healthy and well-educated older adults. Participants who did not progress were more likely to have attended all study visits, suggesting the presence of a healthy survivor effect. This may have contributed to the lack of relationship between health factors and disease progression in this study; hence, conclusions drawn here about the influence of these aspects of health on late-life risk for MCI/dementia should be challenged in similar studies using population-based sampling methods, such as the MCSA, using midlife health risk factors where possible. Although the number of participants retained in AIBL at 8 years was larger than the sample sizes of the other studies at their longest intervals and AIBL had the longest average follow-up time, even longer follow-ups are necessary to elucidate the disease course and risk factors for MCI/dementia. For this reason, it is not known whether those who did not progress over the study period will go on to progress in the future. Furthermore, as A␤-associated progression was the focus on this study, neurodegeneration measures were not examined. Despite these caveats, the current results indicate that A␤+ has strong prognostic value for the development of clinical symptoms of dementia due to AD even when health factors and competing risks for progression are taken into account. APOE 4 carriage provides further predictive value in the presence of elevated A␤; therefore, A␤+ APOE 4 carriers are ideal candidates for early intervention trials of disease-modifying therapies.
